As displayed in Table 1 and Figure 1A, serum ZAG levels were significantly lower in the MetS group than in the central obesity group (7.98 ± 0.94 μg/mL vs. 8.37 ± 1.52 μg/mL, P < 0.05) and the control group (7.98 ± 0.94 μg/mL vs. 8.78 ± 1.66 μg/mL, P < 0.05). This evidence concerns the gene AZGP1 and metabolic syndrome.